This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Star Scientific, Ambac: Early Volume Plays

( Star Scientific item was corrected to reflect it is not a secondary offering. Please see the correction here..)

NEW YORK ( TheStreet) -- Star Scientific (CIGX) registered 18.05 million shares by selling shareholders under a prospectus.

Star Scientific closed Monday at $1.88 and slumped more than 4% in the after-market session after a regulatory filing showed that stockholders could sell up to 18.05 million common shares. Star Scientific said it is not selling any common stock and will not receive any of the proceeds from the sale.

Star Scientific shares have fallen hard since the company announced a collaboration with Roskamp Institute on Beta-amyloid discovery to treat Alzheimer's disease, falling more than 32% since April 8. The 50-day average daily volume for Star Scientific is 4.65 million, according to the Nasdaq.

Elsewhere, Array BioPharma (ARRY - Get Report) jumped by 78 cents, or 25.8%, to $3.80 in the premarket session after the company said it has entered into a $467 million licensing agreement with Novartis (NVS - Get Report) for the development of the cancer drug candidates ARRY-162, ARRY-300 and other small-molecule MEK inhibitors.

Array will initially receive $45 million comprising an upfront and milestone payment and is eligible to receive an additional $422 million if certain clinical, regulatory and commercial milestones are achieved. Array is eligible to receive double-digit royalties on sales of the approved products outside the U.S., and it becomes eligible for a "significantly higher" royalty rate on sales in the U.S. if the company meets co-funding obligations. The 50-day average daily volume for Array BioPharma is 303,000.

FalconStor Software (FALC - Get Report) dropped by 36 cents, or 11%, to $2.90 in the premarket session after the company offered preliminary results for the first quarter, saying it expects a loss of 8 cents to 9 cents a share on revenue of $16.8 million to $17.1 million. Analysts are looking for a loss of 2 cents a share on revenue of $19.4 million, according to Thomson Reuters.

FalconStor said the revenue shortfall is due to lower-than-expected software license revenue, particularly international software sales. The 50-day average daily volume for FalconStor is 160,000.

Ambac Financial (ABK) continued to bounce from its recent pullback, rising by 18 cents, or 9.3%, to $2.12 in the premarket session after shares rose 10.2% during Monday's session.

Ambac rallied on the bond insurer's better-than-expected fourth-quarter results over a week ago, before pulling back on a JPMorgan analyst's comment that the equity is "worthless." The three-month average daily volume for Ambac is 41.58 million, according to Yahoo! Finance.

-- Written by Robert Holmes in Boston.

Check out all of Tuesday's high-volume, under-$5 stocks at the Dollar Store. View the Dollar Store portfolio on StockPickr.

Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CIGX $0.00 0.00%
ARRY $7.64 -1.20%
FALC $1.50 0.67%
NVS $104.23 0.68%
YHOO $43.07 -0.71%

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs